Study on Combining Stereotactic Body Radiotherapy with FAK and RAF/MEK Inhibitors for Advanced Pancreatic Cancer

Inclusion Criteria

• Have advanced pancreatic cancer that cannot be removed by surgery or is difficult to operate on.
• Cancer must be confirmed by lab tests and meet specific medical criteria.
• Have received at least two months of chemotherapy without the cancer getting worse.
• Be 18 years or older.
• Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of more than three months.
• Have adequate blood cell counts and organ function, including:
  • Neutrophil count of at least 1.5 K/cumm.
  • Platelet count of at least 100 K/cumm.
  • Hemoglobin level of at least 9.0 g/dL.
  • Normal liver and kidney function as indicated by specific blood tests.
• Have good heart function with a left ventricular ejection fraction of at least 55%.
• Agree to use effective contraception during the study and for a specified period after treatment.
• Be able to understand and sign a consent form, or have a representative do so on their behalf.

Exclusion Criteria

• Have a history of other cancers unless treatment was completed at least two years ago and there is no evidence of disease.
• Have fluid buildup in the abdomen or around the lungs that requires drainage.
• Have previously received certain types of cancer treatments, including FAK or RAF/MEK inhibitors.
• Have a history of severe allergic reactions to similar drugs used in the study.
• Have an active autoimmune disease requiring treatment in the past two years.
• Have received a live vaccine within 30 days before starting the study.
• Have a history of hepatitis B or active hepatitis C infection.
• Have a history of lung inflammation requiring steroids.
• Have had major surgery within 28 days before starting the study.
• Be pregnant or breastfeeding.
• Have HIV with low CD4+ T-cell counts or a history of certain infections.
• Have had a recent COVID-19 infection.
• Be taking medications that interact with the study drugs.
• Have difficulty swallowing pills or have certain digestive issues.
• Have a history of serious muscle breakdown.
• Have certain eye conditions or heart problems.
• Have any other medical condition that could increase the risk of side effects.
• Have an active infection that is not improving with treatment.
• Have brain metastases requiring treatment with steroids or other interventions.